Trial also achieves statistical significance in key secondary endpoints- Novavax to submit a U.S. BLA under FDA’s accelerated approval pathway
- Company to host investor conference call today at 8:30 a.m. EDT
The post Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial appeared first on Healthier Environment Living Program.